Disruption of Erk-dependent type I interferon induction breaks the myxoma virus species barrier.
about
Myxoma virus M-T5 protects infected cells from the stress of cell cycle arrest through its interaction with host cell cullin-1Replication of subgenomic hepatitis C virus replicons in mouse fibroblasts is facilitated by deletion of interferon regulatory factor 3 and expression of liver-specific microRNA 122Immunomodulatory functions of type I interferonsCytokine synergy: an underappreciated contributor to innate anti-viral immunityOncolytic virus therapy for glioblastoma multiforme: concepts and candidatesAlpha/beta interferon protects against lethal West Nile virus infection by restricting cellular tropism and enhancing neuronal survivalResistance to Alpha/Beta Interferon Is a Determinant of West Nile Virus Replication Fitness and VirulenceThe Marmoset Model of GB Virus B Infections: Adaptation to Host Phenotypic VariationActivation of the PI3K/Akt Pathway Early during Vaccinia and Cowpox Virus Infections Is Required for both Host Survival and Viral ReplicationUp-Regulation of Hepatitis C Virus Replication and Production by Inhibition of MEK/ERK SignalingPoxvirus tropismPathogenesis of noroviruses, emerging RNA virusesMyxoma virus oncolytic efficiency can be enhanced through chemical or genetic disruption of the actin cytoskeletonRIG-I mediates the co-induction of tumor necrosis factor and type I interferon elicited by myxoma virus in primary human macrophagesTargeting gallbladder cancer: oncolytic virotherapy with myxoma virus is enhanced by rapamycin in vitro and further improved by hyaluronan in vivo.Oncolytic viral purging of leukemic hematopoietic stem and progenitor cells with Myxoma virusMechanisms of severe acute respiratory syndrome pathogenesis and innate immunomodulation.Macroevolutionary Immunology: A Role for Immunity in the Diversification of Animal life.Innate immune response of human plasmacytoid dendritic cells to poxvirus infection is subverted by vaccinia E3 via its Z-DNA/RNA binding domainBarriers of hepatitis C virus interspecies transmissionDengue virus serotype 2 blocks extracellular signal-regulated kinase and nuclear factor-κB activation to downregulate cytokine production.Genetic Dissection of the Host Tropism of Human-Tropic Pathogens.A whole-genome RNA interference screen for human cell factors affecting myxoma virus replicationHighly pathogenic H5N1 influenza A virus strains provoke heterogeneous IFN-α/β responses that distinctively affect viral propagation in human cells.Resistance to oncolytic myxoma virus therapy in nf1(-/-)/trp53(-/-) syngeneic mouse glioma models is independent of anti-viral type-I interferon.Poxviral regulation of the host NF-kappaB response: the vaccinia virus M2L protein inhibits induction of NF-kappaB activation via an ERK2 pathway in virus-infected human embryonic kidney cells.Myxoma virus is a novel oncolytic virus with significant antitumor activity against experimental human gliomas.Myxoma virus oncolysis of primary and metastatic B16F10 mouse tumors in vivo.Myxoma virus induces type I interferon production in murine plasmacytoid dendritic cells via a TLR9/MyD88-, IRF5/IRF7-, and IFNAR-dependent pathway.Histological evaluation of intratumoral myxoma virus treatment in an immunocompetent mouse model of melanoma.M135R is a novel cell surface virulence factor of myxoma virusOncolytic virotherapy synergism with signaling inhibitors: Rapamycin increases myxoma virus tropism for human tumor cells.A vaccinia virus-driven interplay between the MKK4/7-JNK1/2 pathway and cytoskeleton reorganizationNS1 proteins of avian influenza A viruses can act as antagonists of the human alpha/beta interferon response.The vaccinia virus O1 protein is required for sustained activation of extracellular signal-regulated kinase 1/2 and promotes viral virulence.The interferon regulatory factors as novel potential targets in the treatment of cardiovascular diseases.The potential role of fowlpox virus in rational vaccine design.Vesicular stomatitis virus oncolysis of T lymphocytes requires cell cycle entry and translation initiation.Strategies to achieve systemic delivery of therapeutic cells and microbes to tumors.Viruses as anticancer drugs.
P2860
Q24311311-09F6A9B9-D4FC-4476-99BF-2E08B0270E0AQ24611792-9F88A466-ACC6-414C-94A7-D05233143690Q26823904-BCB998E1-A5AE-4542-8646-27B99195A1E4Q26852421-22CBF4E0-8A3F-40F1-B27E-C20C3042F5ADQ27007519-40915F6E-5FCC-4FB0-B504-935585FBBCF3Q27472671-D0F6F434-1572-454F-A2D7-B3C490AFFEBBQ27477539-3FC1E26C-2757-4670-9F93-39D4A5C82AC0Q27488391-D8AB5D35-578A-4DA8-9843-A50D9C604415Q27488801-35C285AD-2A30-4AD1-A30B-F9FD56F36311Q27489886-FA46B11E-2CC2-4194-8600-F55B080F8D34Q28237434-43F971EC-06C9-41F2-AC30-AC358367AB13Q28392368-44AD2C26-0681-4A29-A783-77F683B165DCQ28538172-8F6AB7B0-F41C-471A-B455-C2483620A787Q30845041-5740066A-322A-42E4-A46F-C462E593C758Q33613734-97314AD3-6BE7-4391-BDCF-D5B9C7262D68Q33895494-F0827A2C-7D73-478D-9472-EBE05053ED8AQ34014960-7C952507-4AD3-47DF-912C-781A223E979EQ34261452-CE75FFE9-FC68-4419-9994-951D85551317Q34273718-25929973-476A-4631-BF25-34C5E958F0CBQ34315915-5B3A6D54-A2D3-48B5-9141-13E5D9BA0BDEQ34395385-EDD4174B-E9C4-4B2B-ADA6-C5DB046C7204Q34495762-56439DA4-104A-4B67-BBC1-C26B0D061684Q34585582-7348F83F-C5DF-413A-A6B6-A0E70E8CD1BDQ34602475-775AF7D2-0A52-4430-836C-2978E9F4DE77Q34770256-4CFABA9C-EF22-4740-85C2-400510BB2DCAQ35024097-B817D741-2B6F-4642-A683-F0FE47E58E4DQ35216380-09F5ED6F-4717-4BB0-96A1-F3EDECE59057Q35223458-69D5B874-B0B6-4E4E-A359-002FC7C29046Q35274869-59F4C926-8AA8-44E8-8771-65FA3E9089B9Q35317396-064836DE-31AD-40B1-B386-1EDFF8316540Q35634308-B07F7D6C-89F7-4667-B0C3-11140ADC0E58Q35635226-D1B4C0BC-C3DA-4B00-9556-03ED00E3D438Q35666007-397A1073-1731-48C2-B684-F6DCD8DBBE67Q35784659-5CDE0EB8-C0D7-448C-A39F-1E01D85EC3BAQ35826480-1B6DF260-E8EB-415C-B461-E39F07460B6FQ36342106-5E4748B5-82AF-49D6-8D32-3A8DD27DD1F9Q36600376-9A50310B-1303-4B60-B5DD-BA5A49968E5DQ36673201-63238F88-98D7-4E51-948F-EDDFE0299A41Q36675446-7D688CC3-4B8E-48A5-90F7-6E1D22B3FAFAQ36850878-39129386-3A07-4417-8DC2-1A6AB1F9DA03
P2860
Disruption of Erk-dependent type I interferon induction breaks the myxoma virus species barrier.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Disruption of Erk-dependent ty ...... myxoma virus species barrier.
@en
Disruption of Erk-dependent ty ...... myxoma virus species barrier.
@nl
type
label
Disruption of Erk-dependent ty ...... myxoma virus species barrier.
@en
Disruption of Erk-dependent ty ...... myxoma virus species barrier.
@nl
prefLabel
Disruption of Erk-dependent ty ...... myxoma virus species barrier.
@en
Disruption of Erk-dependent ty ...... myxoma virus species barrier.
@nl
P2093
P2860
P356
P1433
P1476
Disruption of Erk-dependent ty ...... myxoma virus species barrier.
@en
P2093
Erik Barton
John W Barrett
Xiujuan Gao
P2860
P304
P356
10.1038/NI1132
P407
P577
2004-10-24T00:00:00Z